Find out how AI influences drug discovery, enabling earlier predictions and reducing the risks in clinical development.

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

This publication adds to a growing body of external evidence validating the technical rigor, performance, and real-world relevance of BostonGene's AI-driven approach. By evaluating algorithmic and ...

AI has fundamentally altered the feasibility of natural product discovery from fungal endophytes. Advances in genome ...

GUEST COMMENTARY—For millions of patients, the slow pace of drug discovery means years – sometimes decades – without effective treatments. Many diseases remain untreatable, not because they are rare ...

The MarketWatch News Department was not involved in the creation of this content. -- Oversubscribed GBP2.5M seed round led by Ahren Innovation Capital -- Strategic collaboration with o2h to progress ...

High-resolution analytical platforms, proteomics-driven workflows, and expanding CRO outsourcing reshape strategic priorities ...

AI and genetics are creating a 'seismic shift' in the pharmaceutical business, experts on Asian Financial Forum panel say ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

The field of cancer research has increasingly focused on the metabolic underpinnings of tumorigenesis, recognizing how the reprogramming of cellular energy ...